. 2019 Jan 3;58(6):1025–1033. doi: 10.1093/rheumatology/key417

Table 2.

Correlation between TA disease activity or MDA status and change in mTSS at week 24

Disease activity measure^a	Treatment	n	Correlation (95% CI)	P-value
TA-DAS28(CRP)	PBO	152	0.351 (0.202, 0.482)	<0.001
TA-DAS28(CRP)	ADA	144	0.123 (−0.042, 0.280)	0.144
TA-DAPSA	PBO	152	0.338 (0.188, 0.471)	<0.001
TA-DAPSA	ADA	144	0.141 (−0.023, 0.298)	0.091
TA-PASDAS	PBO	150	0.300 (0.146, 0.438)	<0.001
TA-PASDAS	ADA	136	0.076 (−0.094, 0.241)	0.381
MDA	PBO	146	−0.078 (−0.237, 0.086)	0.353
MDA	ADA	139	−0.020 (−0.186, 0.147)	0.815

TA-DAS28(CRP), TA-DAPSA and TA-PASDAS assessed using Pearson correlation; MDA assessed using biserial correlation. ADA: adalimumab; DAS28: Disease Activity Score of 28 joints; MDA: minimal disease activity; mTSS: modified total Sharp score; DAPSA, Disease Activity Index for Psoriatic Arthritis; PASDAS: Psoriatic Arthritis Disease Activity Score; PBO: placebo; TA: time averaged.